IRIS
VIGNERI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.752
EU - Europa 2.842
AS - Asia 687
AF - Africa 367
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 3
Totale 7.660
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.527
IT - Italia 860
IE - Irlanda 767
UA - Ucraina 568
CN - Cina 539
CI - Costa d'Avorio 238
CA - Canada 223
DE - Germania 210
RU - Federazione Russa 152
SN - Senegal 110
SE - Svezia 63
GB - Regno Unito 52
VN - Vietnam 51
BE - Belgio 44
IN - India 32
FR - Francia 24
NL - Olanda 22
CH - Svizzera 20
NG - Nigeria 18
IR - Iran 14
UZ - Uzbekistan 14
GR - Grecia 13
SG - Singapore 12
PL - Polonia 11
AT - Austria 10
LB - Libano 8
ES - Italia 6
FI - Finlandia 6
IL - Israele 5
AU - Australia 4
BG - Bulgaria 4
EU - Europa 4
CZ - Repubblica Ceca 3
BR - Brasile 2
OM - Oman 2
RO - Romania 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BH - Bahrain 1
GL - Groenlandia 1
HK - Hong Kong 1
ID - Indonesia 1
JP - Giappone 1
MA - Marocco 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
PY - Paraguay 1
SA - Arabia Saudita 1
TH - Thailandia 1
TR - Turchia 1
Totale 7.660
Salva come PNG Salva come JPEG
Città #
Chandler 840
Dublin 767
Jacksonville 648
Catania 273
Abidjan 238
Cambridge 207
Lawrence 204
Nanjing 200
Andover 194
Toronto 156
Grafing 135
Ashburn 128
Des Moines 112
Dakar 110
San Mateo 101
Boardman 89
Wilmington 86
Ottawa 55
Nanchang 51
Hebei 47
Shenyang 46
Dong Ket 40
Saint Petersburg 38
Bremen 34
Portland 33
Milan 32
Brussels 31
Changsha 30
Jiaxing 30
Palermo 29
Seattle 28
Falls Church 26
Tianjin 26
Abuja 18
Pune 18
Quintano 16
Rome 16
Moscow 15
Houston 14
Frankfurt Am Main 13
Santa Venerina 13
Augusta 12
Bari 12
Jinan 12
Hanoi 11
Leawood 11
Norwalk 11
Woodbridge 11
Ardabil 10
Gioiosa Marea 10
Hangzhou 10
Kunming 10
Rotterdam 10
Verona 10
Izegem 9
Los Angeles 9
Messina 9
Ningbo 9
Siracusa 9
Zhengzhou 9
Aci Sant'Antonio 8
Liberty Lake 8
Padova 8
Aci Catena 7
Acireale 7
Cosenza 7
Den Haag 7
Fantina 7
Redmond 7
Washington 7
Ann Arbor 6
Beijing 6
Hanover 6
Lappeenranta 6
Richmond 6
Singapore 6
Aci Castello 5
Giardini-Naxos 5
Grammichele 5
Miami 5
Milazzo 5
Monmouth Junction 5
Taizhou 5
Bengaluru 4
Boydton 4
Fairfield 4
Florence 4
Frankfurt am Main 4
Gravina di Catania 4
Guangzhou 4
Paternò 4
Ragusa 4
Temse 4
Zafferana Etnea 4
Bedford 3
Catanzaro 3
Chicago 3
Edinburgh 3
Groningen 3
Lanzhou 3
Totale 5.587
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 83
Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny 77
Glioblastoma, IDH-Wild Type With FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review 77
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 63
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 62
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 61
Biomarkers and prognostic factors for malignant pleural mesothelioma 58
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 58
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 57
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 57
A Case of Non-Irradiated Balloon Cell Melanoma of the Choroid: Expanding the Morphological Spectrum of Primary Uveal Melanomas 57
RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features 56
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 55
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 55
Heavy metals in the volcanic environment and thyroid cancer 54
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 53
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 53
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells 52
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 52
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 52
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 52
Anaplastic thyroid cancer in sicily: The role of environmental characteristics. 52
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 51
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 51
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 51
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 51
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 50
Hypoxia Induces Imatinib Resistance in CML Cell Lines 50
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 50
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 50
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA 50
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 49
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 49
Uncommon long-term survival in a patient with chronic myeloid leukemia 48
Early occurrence of a thyroid carcinoma in a patient who developed Graves’ disease after treatment for Hodgkin’s disease 48
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 47
Exclusion of c-Abl from the Nucleus Restrains the p73 Tumor Suppression Function 47
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 47
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 47
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 47
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 47
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 46
BCR-ABL tyrosine kinase activity modulates survivin expression via PI3K/AKT 46
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 46
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 46
Late Breaking Abstract - Comparison of VATS debulking surgery and HITHOC vs VATS talc pleurodesis alone in malignant pleural mesothelioma: a pilot study 46
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 46
Basal insulin and cardiovascular and other outcomes 45
Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL 45
BCR-ABL tyrosine kinase activity modulates Survivin expression in CML cells 45
BCR-ABL modifies the expression and function of the IRF-5 transcription factor 45
Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma 45
p73 tumor-suppressor activity is impaired in human thyroid cancer 44
Several site-specific cancers are increased in the volcanic area in Sicily 44
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part I: MR imaging with pathologic correlation and technical considerations 44
INVOLVEMENT OF THE P53 HOMOLOGOUS P73 IN THYROID CANCER PROGRESSION 44
The PU.1 transcription factor induces cyclin D2 expression in U937 cells 43
New insights in thyroid cancer and p53 family proteins 43
Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma 43
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 42
The p53-homologue p63 may promote thyroid cancer progression 42
L’apoptosi indotta da BCR-ABL nucleare richiede p73 42
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 42
HMGA1 inhibits the function of p53 family members in thyroid cancer cells 42
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 41
Cancer stem cells and chemosensitivity 41
Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients 41
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY PATIENTS WITH IMATINIB-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA 41
Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs 41
Silencing of survivin induced by BCR-ABL/JAK2/STAT3 pathway kills CML cells and sensitizes IM-resistant clones to hydroxyurea 41
Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients 41
Increased thyroid cancer incidence in volcanic areas: A role of increased heavy metals in the environment? 41
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 40
Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells 40
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 40
Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria 40
MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS (M-MDSC) AS PROGNOSTIC FACTOR IN DASATINIB TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA 40
Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded 40
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib 39
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 39
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 39
Ground glass opacities management in the lung cancer screening era 39
Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas 39
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 39
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up 38
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 38
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 38
Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression 38
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 38
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 38
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 38
ENDOMETRIAL STROMAL TUMOR (SARCOMA) WITH LIMITED MIOMETRIAL INFILTRATION: A RARE CASE WITH PELVI-PERITONEAL METASTASES 38
Histopathologic and mr imaging appearance of spontaneous and radiation-induced necrosis in uveal melanomas: Initial results 38
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 38
Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia 37
Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML 37
null 37
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 37
Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers 37
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 37
Totale 4.646
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.344
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.344
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201940 0 0 0 0 0 0 0 0 0 0 6 34
2019/2020981 347 57 71 17 82 21 89 13 91 14 102 77
2020/20211.259 16 92 141 15 306 36 136 6 235 4 185 87
2021/20221.503 156 203 22 20 230 37 224 49 137 28 56 341
2022/20232.803 229 144 58 296 224 464 32 542 639 20 95 60
2023/20241.022 110 220 54 79 79 258 34 86 10 67 25 0
Totale 8.028